Product Design Quality Senior Specialist 1

Zimmer Biomet to showcase Complete Shoulder solution designed to support surgeon flexibility. September 18, 2026 (WARSAW, Ind.) Sept. 18, 2026 - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced it will showcase its Complete Shoulder Solutions at the 16th International Congress of Shoulder and Elbow Surgery (ICSES 2026). Every shoulder case may bring its own clinical considerations. Zimmer Biomet's shoulder technologies are designed to give those surgeons the flexibility to select an approach that fits the patient, procedure and care setting. Zimmer Biomet will showcase robotic-assisted surgery, mixed reality navigation, pre-operative planning software, implant systems for anatomic and reverse arthroplasty and sports medicine technologies, including biologics. The updated ROSA(R) Shoulder System, which received expanded U.S. FDA 510(k) clearance in May 2026 is the industry's first robotic system to support both glenoid and humeral preparation for anatomic and reverse total shoulder arthroplasty techniques.[1][-2] The system adds improved robotically assisted glenoid reaming and humeral resection capabilities, building on the existing ROSA Shoulder platform. It uses digital tools to navigate patient anatomy and cross-validate findings to help reduce reliance on manual estimation. The system's data also integrates with the mymobility(R) Care Management Platform to leverage pre-, intra- and post-operative data. The goal is to provide surgeons with data they can use to inform decisions throughout the patient journey, supporting a more personalized and measurable approach to care. "The foundation of the ROSA Shoulder System is grounded in real-world surgeon insights," said Brian Hatcher, President, Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic. "We partnered closely with leading shoulder surgeons, listening to their experiences in the operating room to understand exactly what they need in the moments that matter: visibility, precision, efficiency and flexibility." Also on display at ICSES is Signature Vision(TM), a compact, surgeon-centric mixed reality system designed to deliver real-time holographic feedback on instrument positioning relative to the surgical plan. It can also fit into smaller surgical environments without rearranging staff flow or setup. Navigation lives in the surgeon's line of sight rather than on a separate screen. The system is compatible with a broad implant portfolio; Signature Vision extends confidence through technology designed to work with implants surgeons know and trust. "As shoulder arthroplasty volumes continue to grow, we want to make sure surgeons have more than one way to close the gap between what they plan and what they deliver," said Hatcher. "This year's ICSES exhibit reflects Zimmer Biomet's commitment to delivering a complete shoulder solution approach from innovative pre-operative planning and robotic technologies to soft tissue repair and total shoulder arthroplasty." Products and technologies on display at [Booth 404] will include: Robotics and Navigation * The ROSA(R) Shoulder System - robotically assisted total shoulder arthroplasty for anatomic and reverse procedures with expanded glenoid reaming and humeral resection capabilities * Signature Vision(TM)- compact mixed reality navigation delivering real-time holographic guidance for shoulder arthroplasty (in surgeon evaluation) Upper Extremities * Identity(R) Shoulder System - dynamic platform system designed to enable the surgeon to tailor the construct to the patient in front of them in anatomic, reverse and revision cases. * Comprehensive(R) Shoulder System - including Augmented Baseplates, Vault Reconstruction System (VRS(TM) and Segmental Revision System (SRS); the Comprehensive Reverse has the highest long-term survivorship rate of any reverse shoulder system in the AOANJRR registry. In its 2025 Annual Report, the AOANJRR showed Comprehensive Reverse had a 10-year survivorship rate of 96.6%.[4] * OsseoFit(R) Stemless Shoulder System - bone-preserving implant designed to match the asymmetric humeral anatomy,[3-5] optimizing fit with left- and right-side options in five sizes for anatomic shoulder arthroplasty * Signature(TM) ONE Planner - 3D CT-based planning software designed to streamline pre-operative workflows with simulated join assessments and efficient case plan turnaround times[6] Sports Medicine * OsseoCoat(TM) JuggerKnot(R) Soft Anchor System, Tapestry(R) Biointegrative Implant, ActivBraid(R) Collagen-UHMWPE Suture and Genie(TM) Knotless Anchors - all part of the ZB-3(TM) Biologic Continuum for rotator cuff repair, spanning anchor, suture and biologic technologies About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. Ortho Spine News seamlessly transform the patient experience through its innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Its legacy continues to come to life today through its progressive culture of evolution and innovation. Signature Vision Legal Manufacturer: MR Surgical Solutions, LLC, Bubenbergstrasse 1, 3rd Floor, 8045 Zurich - CH Cautionary Statement Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Published September 18, 2026 January 5, 2015 January 6, 2015

Zimmer Biomet 'restructuring' plan involves 580 cut jobs. Zimmer Biomet plans to cut 580 of 730 positions at its Winterthur, Switzerland facility as part of a broader restructuring plan. Claire Wallace, Senior Writer, Informa Markets - Engineering September 15, 2026 Warsaw, Indiana-based orthopedic leader Zimmer Biomet has announced plans to cut 580 of the 730 positions at its Winterthur, Switzerland manufacturing facility. This is a 3.4% workforce cut to positions worldwide. According to a statement from the company, it is working with consultants to evaluate alternatives to these job cuts. "We continually review our global supply chain network to ensure we are best positioned to serve our customers and their patients and strengthen the business for the long term," Elizabeth Gauthier, manufacturing director at Zimmer Switzerland Manufacturing GmbH, said in a release. The move is part of a broader restructuring effort by the company to improve efficiency and streamline its manufacturing arm. Zimmer Biomet originally acquired the Winterthur facility in 2003 when it acquired Centerpulse, a Switzerland-based company that specialized in orthopedic, spine, and dental implants. The acquisition, totaling 4.5 billion Swiss francs, made Zimmer Biomet the world's largest orthopedics company at the time. The site then became Zimmer's headquarters in the region. This is not the first time jobs have been cut at the site. In 2020, the company relocated 130 management positions from Winterthur to Zug, Switzerland, and in 2022, it cut 73 jobs. Along with the layoffs, Zimmer Biomet is planning to restructure its leadership team to streamline American and global business organizations. As part of the restructure, the company is replacing all of its independent contractors with full-time workers. Early in the year Zimmer Biomet management mentioned that roughly 66%, or two-thirds, of its U.S. sales force (roughly 2,500 people) were 1099s, or independent contractor sales reps. Beginning on October 1, Zimmer will promote Gary Campbell to president, Americas, Brian Hatcher to president, recon, S.E.T., CMFT, neuro and biosurgery, and Bradley Kessler to president, Americas, robotics, technology and data. Zimmer's current group president, global businesses and the Americas, Kevin Thornal, will leave his role before October 1. Despite the shakeups, Zimmer has reiterated its full-year 2026 financial outlook. The last year has been one of transition for the company. "We had a very strong first quarter," Ivan Tornos, the company's president, CEO, and chairman of the board, told analysts during the question-and-answer portion of Zimmer Biomet's first-quarter earnings call. "And as I sit here looking at the next three quarters, the word that comes to mind is 'confident.' I'm very confident that we're moving in the right direction." "We are making fairly substantial changes on a variety of fronts," he said, noting changes in the company's go-to-market models in the United States and some changes in emerging markets, namely China. "We're making investments in innovation at a bold pace. We're hiring people. We're making talent changes," Tornos said. "So, we feel even though the first quarter was very strong, it's probably prudent to wait, let's call it 90 days, and then have the conversation again." Senior Writer, Informa Markets - Engineering Claire Wallace is a senior staff writer at Medical Device + Diagnostics Industry (MD+DI), where she covers key developments in the healthcare and medical device industry. With nearly a decade of journalism experience, she brings a deep understanding of the healthcare industry and a proven ability to connect with physicians, medtech leaders, and policy experts on the issues shaping care delivery today. She is committed to delivering nuanced coverage that helps industry professionals anticipate trends, understand regulatory shifts, and identify opportunities in an increasingly complex healthcare ecosystem. Before joining MD+DI, Claire spent three years at Becker's Healthcare as a writer and assistant editor, leading coverage on developments across orthopedics, outpatient care, cardiology, and gastroenterology that bridged perspectives from clinicians and healthcare executives. Her reporting background also includes lifestyle, political, and clean energy news, with bylines in various national and digital publications. Claire earned her bachelor's degree in Communications and Media & Screen Studies from Northeastern University, where she also minored in Political Science and Journalism. She holds a master's degree in Media Advocacy and is currently based in Chicago. Want more MD+DI in your search results? Editors' choice. Sep 21, 2026 Sponsored Content Sep 21, 2026